Axovant’s trial results are the last major results to come out in 2017, with the next ones reading out in 2018 and a major wave of results expected in 2019.

Source: What Alzheimer’s disease drugs are in development next trial – Business Insider

Alzheimer; News from the web:

Fresh evidence that the body’s immune system interacts directly with the brain could lead to a new understanding of diseases from multiple sclerosis to Alzheimer’s.

A study of human and monkey brains found lymphatic vessels — a key part of the body’s immune system — in a membrane that surrounds the brain and nervous system, a team reported Tuesday in the online journal eLife.

Read all about it HERE

Alzheimer; News from the web:

To bolster the connections between benchside and bedside, the National Institutes of Health National Institute on Aging has awarded Rensselaer Polytechnic Institute a five-year $1.5 million training grant to support a new Alzheimer’s Disease Clinical and Translational Research Training Program. The program positions Rensselaer students to contribute to Alzheimer’s research by exposing them to a range of biotechnology and lighting research on neurodegenerative diseases, including a summer clinical rotation in medical research at the Icahn School of Medicine at Mount Sinai, with whom Rensselaer has an existing partnership.

Read all about it HERE